Minimal Residual Disease (MRD) detection and monitoring hold great promise to be used in clinical trials and beyond patient therapy selection. If single nucleotide variants (SNVs) are detected early on, then better patient stratification and treatment options may be employed to try and prevent relapse. Dr. Asiri Ediriwickrema, from Ravindra Majeti lab at Stanford University, showcases his recent publication in the journal Blood Advances, where they consider how single-cell DNA sequencing enhances MRD detection.
